Leerink Partnrs Has Optimistic Outlook of PTCT Q1 Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Leerink Partnrs lifted their Q1 2025 EPS estimates for PTC Therapeutics in a research report issued on Tuesday, May 6th. Leerink Partnrs analyst J. Schwartz now anticipates that the biopharmaceutical company will earn $10.04 per share for the quarter, up from their previous forecast of ($1.47). The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share. Leerink Partnrs also issued estimates for PTC Therapeutics’ Q2 2025 earnings at ($0.96) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.04) EPS, FY2025 earnings at $8.89 EPS and FY2026 earnings at ($2.99) EPS.

A number of other research analysts have also weighed in on the company. Cantor Fitzgerald cut their price objective on PTC Therapeutics from $113.00 to $112.00 and set an “overweight” rating on the stock in a report on Wednesday. Morgan Stanley reissued an “overweight” rating and set a $70.00 price target (up from $67.00) on shares of PTC Therapeutics in a research report on Friday, March 7th. Royal Bank of Canada upped their price objective on shares of PTC Therapeutics from $57.00 to $58.00 and gave the company an “outperform” rating in a report on Wednesday. JPMorgan Chase & Co. reduced their target price on shares of PTC Therapeutics from $75.00 to $67.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, Scotiabank assumed coverage on shares of PTC Therapeutics in a report on Friday, March 7th. They issued a “sector perform” rating and a $55.00 price target on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, PTC Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $60.92.

PTC Therapeutics Price Performance

Shares of PTCT stock opened at $42.54 on Friday. The business has a fifty day moving average of $49.01 and a 200 day moving average of $46.96. PTC Therapeutics has a 1 year low of $28.72 and a 1 year high of $58.38. The firm has a market capitalization of $3.37 billion, a price-to-earnings ratio of -7.16 and a beta of 0.52.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share for the quarter, topping the consensus estimate of $0.85 by $9.19. The company had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $437.16 million. The firm’s revenue for the quarter was down 9.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.20) EPS.

Insider Activity at PTC Therapeutics

In other news, CFO Pierre Gravier sold 1,168 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total value of $58,516.80. Following the completion of the sale, the chief financial officer now directly owns 75,603 shares in the company, valued at $3,787,710.30. The trade was a 1.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Lee Scott Golden sold 795 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total value of $39,829.50. Following the transaction, the executive vice president now owns 77,856 shares in the company, valued at $3,900,585.60. This trade represents a 1.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,305 shares of company stock worth $1,682,755 in the last 90 days. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of PTC Therapeutics

Institutional investors have recently modified their holdings of the stock. Smartleaf Asset Management LLC lifted its stake in PTC Therapeutics by 78.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 270 shares in the last quarter. Sterling Capital Management LLC lifted its holdings in PTC Therapeutics by 424.4% in the 4th quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 522 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of PTC Therapeutics by 86.3% in the first quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 441 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in shares of PTC Therapeutics during the 4th quarter worth approximately $68,000. Finally, GF Fund Management CO. LTD. purchased a new position in PTC Therapeutics during the fourth quarter worth approximately $73,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.